A Canadian company has now made some discoveries with intriguing implications for the clinical psychedelic industry.
On Wednesday, Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) announced the discovery of three novel families of non-tryptamine psychedelic compounds.
The company says that its research into new chemical structures outside the realm of classic psychedelic drugs was undertaken with intentions of developing superior neuropsychiatric medications.
Photo via Mindset Pharma
Read more: Mindset Pharma develops patent-pending new technology
Read more: Beond publishes ‘Ibogaine: A Clinical Summary’
Mindset Pharma is a Toronto-based research and development company dedicated to psychedelic drug discovery and development for the treatment of psychiatric and neurological disorders.
Through the use of a so-called fragment-based drug discovery (FBDD) method in unison with a specific medicinal chemistry strategy, the scientists at Mindset have designed and developed three novel, chemically unique, small molecule “non-tryptamine scaffolds” designated as Families 6, 7 and 8.
Additionally, the company has filed provisional patent applications for those three drug families that have yielded favourable freedom-to-operate (FTO) searches with no infringements. Mindset says that some of these new compounds could potentially exhibit improved central nervous system (CNS) penetration and efficacy when administered orally.
“Mindset’s leading drug discovery engine continues to yield innovations with the potential to help patients across the world with neuropsychiatric and neurological disorders. The discovery of new Families 6, 7 and 8 demonstrates our commitment to expanding our Research & Development and strengthening our Intellectual Property (IP) portfolio beyond the classical tryptamines in the psychedelic field,” said James Lanthier, CEO of Mindset Pharma.
“The discovery of these new families further expands our rich pipeline and provides a unique serotonergic receptor profile supporting our goal to design new and elegant drug candidates with increased receptor selectivity and potency profiles. Pre-clinical screening of the new families has shown promising results thus far and we are eagerly looking forward to advancing Mindset’s continued innovations into these new, chemically distinct drug families.”
————————————————–
